Intalight™ Receives CE Mark for the Advanced DREAM OCT™ Imaging System

Intalight™ Achieves CE Mark for Revolutionary DREAM OCT™ Imaging

Intalight™, a pioneering company in cutting-edge ophthalmic technologies, has recently announced that it has received the prestigious CE mark for its DREAM OCT™ platform. This significant achievement allows the company to market its advanced optical coherence tomography (OCT) technology in the European Union, benefitting ophthalmologists and their patients with enhanced imaging capabilities.

The DREAM OCT™ system stands for depth, rapid scanning, extensive range, accurate results, and multimodal imaging. This revolutionary platform is designed to deliver the highest quality OCT images available on the market today, allowing for unprecedented visualization of the vascular membrane, retina, and templated vitreous body.

Features and Benefits of DREAM OCT™

The DREAM OCT™ system is capable of ultra-wide field single-shot scanning, providing a remarkable 130-degree OCTA image. With the ability to perform deep scans of up to 12mm, the platform ensures comprehensive imaging of theplex ocular structures with unmatched clarity. Moreover, its deep anterior scanning capacity reaches up to 16.2mm, enabling a thorough examination of the anterior segment from the cornea to the front of the vitreous body all in one sweep.

"Receiving the CE mark in Europe is a proud milestone for Intalight, and it allows us to deliver state-of-the-art technology to ophthalmologists, leading to improved outcomes for their patients," stated Shawn Peng, Chairman and Founder of Intalight.

According to Bing Li, CEO and Co-founder, the technology was developed in direct response to feedback from eye care professionals who are demanding solutions that combine speed, precision, and depth in visualization. DREAM OCT™ offers a comprehensive array of imaging modalities to tackle the most challenging clinical and research applications, exceeding the current standards of care in the field.

Moreover, Intalight has a proven track record with over 160 peer-reviewed articles that have utilized results from the DREAM OCT™ devices, showcasing its effectiveness and reliability in clinical practice.

Future Prospects and Global Expansion

The significance of this approval extends beyond Europe, as Intalight is now poised to seek FDA approval in the United States. Joe Garibaldi, Chief Commercial Officer, expressed excitement about the European approval, stating, "We look forward to continuing our growth with our prestigious network of global institutions and ophthalmologists fueled by this recent CE marking and the future FDA approval."

Intalight is committed to advancing the field of ophthalmology through ongoing collaboration with leading retinal academic institutes and private practices across the United States, Europe, and Asia.

About Intalight

Founded by a team of scientists and industry veterans from Silicon Valley, Intalight Inc. focuses on developing the most advanced ophthalmologic technologies. With operational facilities located in Silicon Valley, Shanghai, and Luyuan, the company’s DREAM OCT™ technology has become an indispensable tool for many ophthalmologists, enhancing both routine clinical use and pushing the boundaries of research.

For more information about Intalight and the DREAM OCT technology, visit Intalight’s official website and follow them on their social media platforms such as LinkedIn and Facebook.